Search Results - "Daniela Di, Pinto"

Refine Results
  1. 1

    Osteosarcoma in Children: Not Only Chemotherapy by Argenziano, Maura, Tortora, Chiara, Pota, Elvira, Di Paola, Alessandra, Di Martino, Martina, Di Leva, Caterina, Di Pinto, Daniela, Rossi, Francesca

    Published in Pharmaceuticals (Basel, Switzerland) (13-09-2021)
    “…Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized…”
    Get full text
    Journal Article
  2. 2

    The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma by Bellini, Giulia, Di Pinto, Daniela, Tortora, Chiara, Manzo, Iolanda, Punzo, Francesca, Casale, Fiorina, Rossi, Francesca

    Published in Current cancer drug targets (01-01-2017)
    “…Osteosarcoma is the most frequent malignant bone tumor in childhood and young adulthood. Long-term survivors of osteosarcoma patients show high prevalence of…”
    Get more information
    Journal Article
  3. 3

    Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition by Giliberti, Giulia, Marrapodi, Maria Maddalena, Di Feo, Giuseppe, Pota, Elvira, Di Martino, Martina, Di Pinto, Daniela, Rossi, Francesca, Di Paola, Alessandra

    “…Osteosarcoma (OS) is the most severe bone tumor in children. A chemotherapy regimen includes a combination of high-dose Methotrexate (MTX), doxorubicin, and…”
    Get full text
    Journal Article
  4. 4

    Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells by Punzo, Francesca, Bellini, Giulia, Tortora, Chiara, Pinto, Daniela Di, Argenziano, Maura, Pota, Elvira, Paola, Alessandra Di, Martino, Martina Di, Rossi, Francesca

    Published in Oncotarget (18-02-2020)
    “…Tumor-associated macrophages and their alternative activation states together with cytokines and growth factors trapped in tumor microenvironment contribute to…”
    Get full text
    Journal Article
  5. 5

    Osteoporosis in Childhood Cancer Survivors: Physiopathology, Prevention, Therapy and Future Perspectives by Rossi, Francesca, Tortora, Chiara, Paoletta, Marco, Marrapodi, Maria Maddalena, Argenziano, Maura, Di Paola, Alessandra, Pota, Elvira, Di Pinto, Daniela, Di Martino, Martina, Iolascon, Giovanni

    Published in Cancers (06-09-2022)
    “…The improvement of chemotherapy, radiotherapy, and surgical interventions, together with hematopoietic stem cell transplantation, increased childhood cancer…”
    Get full text
    Journal Article
  6. 6

    Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors by Rossi, Francesca, Tortora, Chiara, Di Martino, Martina, Di Paola, Alessandra, Di Pinto, Daniela, Marrapodi, Maria Maddalena, Argenziano, Maura, Pota, Elvira

    Published in PloS one (21-07-2022)
    “…Childhood cancer survivors (CCS) are predisposed to the onset of osteoporosis (OP). It is known that iron overload induces osteoclasts (OCs) overactivity and…”
    Get full text
    Journal Article
  7. 7

    Biological Aspects of Inflamm-Aging in Childhood Cancer Survivors by Rossi, Francesca, Di Paola, Alessandra, Pota, Elvira, Argenziano, Maura, Di Pinto, Daniela, Marrapodi, Maria Maddalena, Di Leva, Caterina, Di Martino, Martina, Tortora, Chiara

    Published in Cancers (30-09-2021)
    “…Anti-cancer treatments improve survival in children with cancer. A total of 80% of children treated for childhood cancer achieve 5-year survival, becoming…”
    Get full text
    Journal Article
  8. 8

    Can Denosumab be used in combination with Doxorubicin in Osteosarcoma? by Punzo, Francesca, Tortora, Chiara, Argenziano, Maura, Pinto, Daniela Di, Pota, Elvira, Martino, Martina Di, Paola, Alessandra Di, Rossi, Francesca

    Published in Oncotarget (14-07-2020)
    “…Osteosarcoma is an aggressive bone tumor of the pediatric age. It is therefore important to improve conventional therapies (chemotherapy and surgery)…”
    Get full text
    Journal Article
  9. 9

    Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia by Argenziano, Maura, Tortora, Chiara, Paola, Alessandra Di, Pota, Elvira, Martino, Martina Di, Pinto, Daniela Di, Leva, Caterina Di, Rossi, Francesca

    Published in Oncotarget (06-07-2021)
    “…Pediatric acute myeloid leukemia (AML) represents 20% of total childhood leukemia diagnoses and is characterized by poor prognosis with a long-term survival…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System by Mascolo, Annamaria, Scavone, Cristina, Bertini, Michele, Brusco, Simona, Punzo, Francesca, Pota, Elvira, Di Martino, Martina, Di Pinto, Daniela, Rossi, Francesca

    Published in Frontiers in pharmacology (07-05-2020)
    “…Among factors influencing the higher risk of developing unknown or rare adverse drug reactions (ADRs) among children and adolescents, there is the frequent…”
    Get full text
    Journal Article
  13. 13

    Effects of Iron Chelation in Osteosarcoma by Argenziano, Maura, Di Paola, Alessandra, Tortora, Chiara, Di Pinto, Daniela, Pota, Elvira, Di Martino, Martina, Perrotta, Silverio, Rossi, Francesca, Punzo, Francesca

    Published in Current cancer drug targets (01-01-2021)
    “…Osteosarcoma is an aggressive bone tumor. It represents the principal cause of cancer-associated death in children. Considering the recent findings on the role…”
    Get more information
    Journal Article
  14. 14

    High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas by Ramaglia, Maria, D'Angelo, Velia, Iannotta, Adriana, Di Pinto, Daniela, Pota, Elvira, Affinita, Maria Carmen, Donofrio, Vittoria, Errico, Maria Elena, Lombardi, Angela, Indolfi, Cristiana, Casale, Fiorina, Caraglia, Michele

    Published in Cancer cell international (28-07-2016)
    “…Enhancer of Zeste Drosophila Homologue 2 (EZH2) is a key regulator of transcription as a member of polycomb repressive complex 2 (PRC2) which exerts repression…”
    Get full text
    Journal Article
  15. 15

    Unusual association of non-anaplastic Wilms tumor and Cornelia de Lange syndrome: case report by Santoro, Claudia, Apicella, Andrea, Casale, Fiorina, La Manna, Angela, Di Martino, Martina, Di Pinto, Daniela, Indolfi, Cristiana, Perrotta, Silverio

    Published in BMC cancer (13-06-2016)
    “…Cornelia de Lange syndrome is the prototype for cohesinopathy disorders, which are characterized by defects in chromosome segregation. Kidney malformations,…”
    Get full text
    Journal Article
  16. 16

    Poikiloderma With Neutropenia and Mastocytosis: A Case Report and a Review of Dermatological Signs by Piccolo, Vincenzo, Russo, Teresa, Di Pinto, Daniela, Pota, Elvira, Di Martino, Martina, Piluso, Giulio, Ronchi, Andrea, Argenziano, Giuseppe, Di Brizzi, Eugenia Veronica, Santoro, Claudia

    Published in Frontiers in medicine (10-06-2021)
    “…Poikiloderma with neutropenia (PN) is a very rare genetic disorder mainly characterized by poikiloderma and congenital neutropenia, which explains the…”
    Get full text
    Journal Article
  17. 17

    Osteonecrosis as a complication in pediatric patients with acute lymphoblastic leukemia by Riccio, Ilaria, Pota, Elvira, Marcarelli, Marco, Affinita, Maria Carmen, Di Pinto, Daniela, Indolfi, Cristiana, Del Regno, Nicola, Esposito, Marco

    Published in La Pediatria medica e chirurgica (28-11-2016)
    “…Osteonecrosis is a significant adverse effect of treatment administered to children suffering from acute lymphoblastic leukemia (ALL) that may have a negative…”
    Get full text
    Journal Article
  18. 18

    Time trends of cancer incidence in childhood in Campania region: 25 years of observation by Indolfi, Paolo, Picazio, Serena, Perrotta, Silverio, Rossi, Francesca, Pession, Andrea, Di Martino, Martina, Pota, Elvira, Di Pinto, Daniela, Indolfi, Cristiana, Rondelli, Roberto, Vetrano, Francesco, Casale, Fiorina

    Published in Italian journal of pediatrics (06-09-2016)
    “…Childhood cancer is relatively uncommon and the European age-standardized rate was 164 new case per million per year among children 0 to 14 years of age (95 %…”
    Get full text
    Journal Article
  19. 19

    Bortezomib and endocannabinoid/endovanilloid system: a synergism in osteosarcoma by Punzo, Francesca, Tortora, Chiara, Di Pinto, Daniela, Pota, Elvira, Argenziano, Maura, Di Paola, Alessandra, Casale, Fiorina, Rossi, Francesca

    Published in Pharmacological research (01-11-2018)
    “…[Display omitted] Osteosarcoma is the most common primary malignant tumor of bone in children and adolescents. Bortezomib (BTZ) is an approved anticancer drug,…”
    Get full text
    Journal Article
  20. 20

    Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma by Punzo, Francesca, Tortora, Chiara, Di Pinto, Daniela, Manzo, Iolanda, Bellini, Giulia, Casale, Fiorina, Rossi, Francesca

    Published in Oncotarget (15-08-2017)
    “…Osteosarcoma is the most common and aggressive bone tumor in children. The Endocannabinoid/Endovanilloid system has been proposed as anticancer target in tumor…”
    Get full text
    Journal Article